Objective: The effect and safety of etoposide combined with G-CSF were compared with those of cyclophosphamide combined with G-CSF in autologous peripheral blood mobilization in patients with multiple myeloma (MM) . Methods: Patients with MM who received autologous peripheral blood stem cell mobilization and collection in the Department of Hematology, Beijing Chaoyang Hospital Affiliated to Capital Medical University from January 1, 2020 to July 31, 2023 were included. A total of 134 patients were screened by propensity score matching technology according to a 1∶1 ratio. A total of 67 cases were each treated with ETO combined with G-CSF mobilization scheme (ETO group) and CTX combined with G-CSF mobilization scheme (CTX group). Their clinical data were retrospectively analyzed. Results: ①Collection results: the ETO and CTX groups [2 (1-3) d vs 2 (1-5) d; P<0.001] and CD34(+) cells [7.62×10(6) (2.26×10(6)-37.20×10(6)) /kg vs 2.73×10(6) (0.53×10(6)-9.85×10(6)) /kg; P<0.001] were collected. The success rate of collection was 100.0% (67/67) versus 76.1% (51/67) (P<0.001). Excellent rate of collection was 82.1% (55/67) versus 20.9% (14/67; P<0.001). Two patients in the ETO group switched protocols after 1 day of collection, and 11 patients in the CTX group switched protocols after 1-2 days of collection. ②Adverse reactions: granular deficiency with fever (21.5%[14/65] vs. 10.7%[6/56]; P=0.110), requiring platelet transfusion [10.7% (7/65) vs 1.8% (1/56) ; P=0.047]. ③Until the end of follow-up, 63 cases in the ETO group and 54 cases in the CTX group have undergone autologous transplantation. The median number of CD34(+) cells infused in the two groups was 4.62×10(6) (2.14×10(6)-19.89×10(6)) /kg versus 2.62×10(6) (1.12×10(6)-5.31×10(6)) /kg (P<0.001), neutrophil implantation time was 11 (9-14) d versus 11 (10-14) d (P=0.049), and platelet implantation time was 11 (0-19) d vs. 12 (0-34) d (P=0.035). One case in the CTX group experienced delayed platelet implantation. Conclusion: The mobilization scheme of etoposide combined with G-CSF requires relatively platelet transfusion, but the collection days are shortened. The collection success rate, excellent rate, and the number of CD34(+) cells obtained are high, and the neutrophil and platelet engraftment is accelerated after transplantation.
目的： 比较依托泊苷（ETO）联合G-CSF与环磷酰胺（CTX）联合G-CSF在多发性骨髓瘤（MM）患者中进行自体外周血造血干细胞动员的效果及安全性。 方法： 纳入2020年1月1日至2023年7月31在首都医科大学附属北京朝阳医院血液科接受自体外周血造血干细胞动员、采集的MM患者，利用倾向性评分按照1∶1匹配比例筛选出134例患者，ETO联合G-CSF动员方案（ETO组）、CTX联合G-CSF动员方案（CTX组）各67例，对其临床资料进行回顾性分析。 结果： ①ETO组、CTX组采集天数分别为2（1~3）d、2（1~5）d（P<0.001），CD34(+)细胞采集量分别为7.62（2.26~37.20）×10(6)/kg、2.73（0.53~9.85）×10(6)/kg（P<0.001），采集成功率分别为100.0%（67/67）、76.1%（51/67）（P<0.001）、采集优良率分别为82.1%（55/67）、20.9%（14/67）（P<0.001）。ETO组有2例患者在采集1 d后进行方案转换，CTX组有11例患者在采集1~2 d后进行方案转换。②ETO组、CTX组粒缺伴发热发生率分别为21.5%（14/65）、10.7%（6/56）（P=0.110），血小板输注患者占比分别为10.7%（7/65）、1.8%（1/56）（P=0.047）。③至随访截止，ETO组63例、CTX组54例患者接受了自体造血干细胞移植，中位CD34(+)细胞回输量分别为4.62（2.14~19.89）×10(6)/kg、2.62（1.12~5.31）×10(6)/kg（P<0.001），中性粒细胞植入时间分别为11（9~14）d、11（10~14）d（P=0.049），血小板植入时间分别为11（0~19）d、12（0~34）d（P=0.035）。CTX组有1例患者发生血小板延迟植入。 结论： 依托泊苷联合G-CSF的动员方案可能有较多的患者需要输注血小板，但采集天数缩短，采集成功率、优良率及CD34(+)细胞采集量较高，移植后中性粒细胞和血小板植入较快。.

This report presents a case involving a woman aged >65 years who had been diagnosed with marginal zone lymphoma 3 years prior. The patient was hospitalized with enlarged inguinal lymph nodes, and pathological examination revealed that the lymphoma had transformed into diffuse large B-cell lymphoma. After two cycles of brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (BV-R-CHP) chemotherapy, the patient achieved complete remission. This treatment was followed by autologous hematopoietic stem cell transplantation and lenalidomide maintenance therapy. At the last follow-up, the patient had been in continuous remission for 24 months. This case study suggests that the utilization of BV and R-CHP in conjunction can result in rapid remission, and it can be followed by autologous hematopoietic stem cell transplantation and maintenance therapy with lenalidomide. This treatment approach exhibits potential as a viable option for older individuals with transformed lymphoma.

OBJECTIVE: Multiple myeloma (MM) is the leading indication of autologous hematopoietic stem cell transplantation. The aim of this study was to determine the incidence of mobilization failure and characterize the risk factors associated with poor mobilization (PM) of MM patients in novel therapies era.
METHODS: We conducted a retrospective study of 211 MM patients who received their first peripheral blood stem cells (PBSC) mobilization at our single center. The following data were collected: age, gender, clinical stage, disease status, complete blood cell count, induction regimen, CD34+ cell count in peripheral blood (PB), and PBSC collections.
RESULTS: In addition to conventional drugs, 22 (10.4%) patients received daratumumab containing induction, and 33 (15.6%) patients used plerixafor for poor mobilization (pre-apheresis PB CD34+ cells <20/μL). Failure of collection occurred in 24 (11.4%) patients and was correlated with low white blood cell (WBC), ≥3 cycles of lenalidomide treatment before mobilization, steady-state mobilization and nouse of plerixafor are associated with mobilization failure. Daratumumab-based induction treatment ≥2 courses, albumin >41 g/L before mobilization, and steady-state mobilization were risk factors for PM in subgroups of patients treated with lenalidomide for <3 courses. In addition, Hepatitis B virus infection at baseline, thalassemia and measurable residual disease positivity were recognized as predictive factors for PM in subset of chemo-mobilization patients.
CONCLUSIONS: In addition to some well-recognized risk factors, baseline WBC count and daratumumab exposure ≥2 courses before mobilization were revealed as the predictive factors of mobilization failure, providing consultation for preemptive use of plerixafor.

Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) has been introduced for the mobilization of peripheral blood stem cells (PBSCs). However, no cases of acute lung injury (ALI) in healthy donors have been reported, and the underlying mechanisms remain poorly understood. We first reported a case of ALI caused by PEG-rhG-CSF in a healthy Chinese donor, characterized by hemoptysis, hypoxemia, and patchy shadows. Ultimately, hormone administration, planned PBSC collection, leukocyte debridement, and planned PBSC collection resulted in active control of the donor\'s ALI. The donor\'s symptoms improved without any adverse effects, and the PBSC collection proceeded without incident. Over time, the lung lesion was gradually absorbed and eventually returned to normal. PEG-rhG-CSF may contribute to ALI in healthy donors via mechanisms involving neutrophil aggregation, adhesion, and the release of inflammatory mediators in the lung. This case report examines the clinical manifestations, treatment, and mechanism of lung injury induced by PEG-rhG-CSF-mobilized PBSCs.

OBJECTIVE: To analyze the effect of recombinant human thrombopoietin (rhTPO) on platelet (PLT) reconstitution after autologous peripheral blood stem cell transplantation (APBSCT) in patients with multiple myeloma (MM).
METHODS: The clinical data of 147 MM patients who were diagnosed in the First Affiliated Hospital of Soochow University and received APBSCT as the first-line therapy were retrospectively analyzed. According to whether rhTPO was used during APBSCT, the patients were divided into rhTPO group (80 cases) and control group (67 cases). The time of PLT engraftment, blood product infusion requirements, the proportion of patients with PLT recovery to≥50×109/L and≥100×109/L at +14 days and +100 days after transplantation, and adverse reactions including the incidence of bleeding were compared between the two groups.
RESULTS: There were no significant differences between the two groups in sex, age, M protein type, PLT count at the initial diagnosis, median duration of induction therapy before APBSCT, and number of CD34+ cells reinfused (all P >0.05). The median time of PLT engraftment in the rhTPO group was 10 (6-14) days, which was shorter than 11 (8-23) days in the control group (P < 0.001). The median PLT transfusion requirement in the rhTPO group during APBSCT was 15(0-50)U, which was less than 20 (0-80)U in the control group (P =0.001). At +14 days after transplantation, the proportions of patients with PLT≥50×109/L in the rhTPO group and the control group were 66.3% and 52.2%, while the proportions of patients with PLT≥100×109/L were 23.8% and 11.9%, respectively, with no significant differences (all P >0.05). At +100 days after transplantation, the proportion of patients with PLT≥50×109/L in rhTPO group and control group was 96.3% and 89.6%, respectively (P >0.05), but the proportion of patients with PLT≥100×109/L in rhTPO group was higher than that in control group (75.0% vs 55.2%, P =0.012). There was no difference in the overall incidence of bleeding events in different locations during period of low PLT level of patients between the two groups. In rhTPO group, the rhTPO administration was well tolerated, and the incidences of abnormal liver and kidney function and infection were similar to those in the control group.
CONCLUSIONS: When MM patients undergo first-line APBSCT, subcutaneous injection of rhTPO can shorten the time of platelet engraftment, reduce the transfusion volume of blood products, and be well tolerated, moreover, more patients have achieve a high level of PLT recovery after transplantation, which is very important for ensuring the safety of APBSCT and maintenance therapy.
UNASSIGNED: 重组人血小板生成素对多发性骨髓瘤患者自体外周血造血干细胞移植术后血小板重建影响的研究.
UNASSIGNED: 分析重组人血小板生成素（rhTPO）对多发性骨髓瘤（MM）患者自体外周血造血干细胞移植术 （APBSCT）后血小板（PLT）重建的影响。.
UNASSIGNED: 回顾性分析在苏州大学附属第一医院一线行APBSCT治疗的147例MM患者的临床资料，根据APBSCT期间是否使用rhTPO分为rhTPO组80例和对照组67例，比较两组患者在PLT植入时间、血制品输注需求量、移植后+14和+100 d PLT恢复至≥50×109/L和≥100×109/L的患者比例以及出血发生率等方面的差异。.
UNASSIGNED: 两组患者在性别、年龄、M蛋白类型、初诊时PLT数、APBSCT前诱导治疗中位疗程数、回输的CD34+细胞数方面均无统计学差异（均P >0.05）。rhTPO组患者PLT植入中位时间为10（6-14）d，较对照组11（8-23）d显著缩短（P < 0.001）。rhTPO组患者在APBSCT期间的中位PLT输注需求量为15（0-50）U，较对照组20（0-80）U更少（P =0.001）。移植后+14 d时rhTPO组和对照组PLT≥50×109/L的患者比例分别为66.3% 和52.2%，PLT≥100×109/L的患者比例分别为23.8%和11.9%，比较差异均无统计学意义（P >0.05）。在移植后+100 d时，rhTPO组和对照组PLT≥50×109/L的患者比例分别为96.3%和89.6%（P >0.05），但rhTPO组PLT≥ 100×109/L的患者比例高于对照组（75.0% vs 55.2%，P =0.012）。两组患者在PLT水平低下期间不同部位出血事件的总体发生率无差异，且rhTPO组治疗耐受性良好，肝肾功能异常和感染的发生概率与对照组类似。.
UNASSIGNED: MM患者在一线行APBSCT时，皮下注射rhTPO药物可以缩短PLT植入时间，减少血制品的需求量，耐受性良好，且在移植后有更多患者达到了PLT高水平的恢复，这对保证APBSCT和MM患者维持治疗期间的安全具有重要意义。.

Objectives: To assess the efficacy of cord blood-assisted haploid peripheral blood stem cell transplantation (haplo-cord-PBSCT) versus unrelated donor peripheral blood stem cell transplantation (UD-PBSCT) in the treatment of malignant hematological diseases. Methods: A retrospective analysis was performed on one hundred and four patients with malignant hematological diseases who underwent haplo-cord-PBSCT and fifty-two patients who underwent UD-PBSCT at Xiangya Hospital of Central South University between January 2016 and December 2021. Results: ①The median implantation time for neutrophils in the haplo-cord-PBSCT and UD-PBSCT groups was 13 (9-22) days and 13 (10-24) days, respectively (P=0.834), whereas the median implantation time for platelets was 15 (7-103) days and 14 (8-38) days, respectively (P=0.816). The cumulative implantation rate of neutrophils at 30 days after transplantation in the haplo-cord-PBSCT group and the UD-PBSCT group was 100% (P=0.314), and the cumulative platelet implantation rate at 100 days after transplantation was 95.2% (95% CI 88.3% - 98.1% ) and 100% (P=0.927), respectively. 30 days after transplantation, both groups of patients achieved complete donor chimerism, and no umbilical cord blood stem cells were implanted. ②The cumulative incidence rates of grade Ⅱ-Ⅳ acute GVHD within 100 days after transplantation in the haplo-cord-PBSCT group and the UD-PBSCT group were 29.1% (95% CI 20.1% -38.1% ) and 28.8% (95% CI 17.2% -41.6% (P=0.965), respectively. The cumulative incidence rates of grade Ⅲ/Ⅳ acute GVHD were 7.8% (95% CI 3.6% -14.0% ) and 9.6% (95% CI 3.5% -19.5% ) (P=0.725). The cumulative incidence rates of 2-year chronic GVHD in the haplo-cord-PBSCT group and the UD-PBSCT group were 45.3% (95% CI 36.1% -56.1% ) and 35.1% (95% CI 21.6% -44.1% ), respectively (P=0.237). The cumulative incidence rates of severe chronic GVHD at 2 years after transplantation were 13.6% (95% CI 7.6% -21.3% ) and 12.9% (95% CI 5.1% -24.3% ), respectively (P=0.840). ③The 2-year CIR after transplantation in the haplo-cord-PBSCT group and UD-PBSCT group were 12.8% (95% CI 7.0% -20.5% ) and 10.0% (95% CI 3.6% -20.2% ), respectively (P=0.341), and the NRM were 14.7% (95% CI 8.4% -22.6% ) and 16.2% (95% CI 7.4% -28.0% ), respectively (P=0.681). ④The 2-year OS rates in the haplo-cord-PBSCT and UD-PBSCT groups after transplantation were 82.2% (95% CI 74.8% -90.3% ) and 75.5% (95% CI 64.2% -88.7% ), respectively (P=0.276). The 2-year DFS rates were 69.9% (95% CI 61.2% -79.8% ) and 73.8% (95% CI 62.4% -87.3% ), respectively (P=0.551). The 2-year rates of GVHD-free/recurrence-free survival (GRFS) were 55.3% (95% CI 44.8% -64.8% ) and 64.7% (95% CI 52.8% -79.3% ), respectively (P=0.284) . Conclusion: The findings of this study indicate that haplo-cord-PBSCT and UD-PBSCT have comparable efficacy and safety in the treatment of malignant hematological diseases and can be used as an alternative treatment options.
目的： 比较脐带血辅助单倍体外周血干细胞移植（haplo-cord-PBSCT）与无关供者外周血干细胞移植（UD-PBSCT）治疗恶性血液病的疗效。 方法： 对中南大学湘雅医院2016年1月至2021年12月的104例接受haplo-cord-PBSCT和52例接受UD-PBSCT）的恶性血液病患者进行回顾性分析。 结果： ①haplo-cord-PBSCT和UD-PBSCT组中性粒细胞中位植入时间分别为13（9～22）d、13（10～24）d（P＝0.834），血小板植入中位时间分别为15（7～103）d、14（8～38）d（P＝0.816）。haplo-cord-PBSCT组和UD-PBSCT组移植后30 d中性粒细胞累积植入率均为100.0%（P＝0.314），移植后100 d血小板累积植入率分别为95.2%（95%CI 88.3%～98.1%）、100.0%（P＝0.927）。移植后30 d两组患者均达到完全供者嵌合状态，未发生脐带血干细胞植入。②haplo-cord-PBSCT组与UD-PBSCT组移植后100 d内Ⅱ～Ⅳ度急性GVHD的累积发生率分别为29.1%（95%CI 20.1%～38.1%）、28.8%（95%CI 17.2%～41.6%（P＝0.965），Ⅲ/Ⅳ度急性GVHD的累积发生率分别为7.8%（95%CI 3.6%～14.0%）、9.6%（95%CI 3.5%～19.5%）（P＝0.725）。haplo-cord-PBSCT组与UD-PBSCT组2年慢性GVHD的累积发生率分别为45.3%（95%CI 36.1%～56.1%）、35.1%（95%CI 21.6%～44.1%）（P＝0.237），移植后2年重度慢性GVHD的累积发生率分别为13.6%（95%CI 7.6%～21.3%）、12.9%（95%CI 5.1%～24.3%）（P＝0.840）。③haplo-cord-PBSCT组、UD-PBSCT组移植后2年CIR分别为12.8%（95%CI 7.0%～20.5%）、10.0%（95%CI 3.6%～20.2%）（P＝0.341），NRM分别为14.7%（95%CI 8.4%～22.6%）、16.2%（95%CI 7.4%～28.0%）（P＝0.681）。④haplo-cord-PBSCT组、UD-PBSCT组移植后2年OS率分别为82.2%（95%CI 74.8%～90.3%）、75.5%（95%CI 64.2%～88.7%）（P＝0.276），2年DFS率分别为69.9%（95%CI 61.2%～79.8%）、73.8%（95%CI 62.4%～87.3%）（P＝0.551），2年无GVHD无复发生存（GRFS）率分别为55.3%（95%CI 44.8%～64.8%）、64.7%（95%CI 52.8%～79.3%）（P＝0.284）。 结论： haplo-cord-PBSCT与UD-PBSCT治疗恶性血液病具有相似的疗效和安全性，可作为恶性血液病的替代治疗方案。.

To evaluate the co-transplantation efficacy of umbilical cord mesenchymal stem cells (UC-MSCs) and peripheral blood stem cells (PBSCs) as a novel approach for refractory or relapsed severe aplastic anemia (R/R SAA) in children and adolescents, thirty-two children and adolescents diagnosed with R/R SAA underwent a retrospective chart review. The patients were categorized into two groups based on the source of PBSCs: the matched sibling donor (MSD) group and the unrelated donor (UD) group. No adverse events related to UC-MSC infusion occurred in any of the patients. The median time for neutrophil engraftment was 13 days (range: 10-23 days), and for platelets, it was 15 days (range: 11-28 days). Acute GVHD of Grade I-II and moderate chronic GVHD were observed in 21.8 and 12.5% of cases, respectively. No statistically significant differences were found between the MSD and UD groups in terms of engraftment, GVHD, and complications, including infection and hemorrhagic cystitis. The median follow-up time was 38.6 months (range: 1.4-140.8 months). As of October 31, 2021, five patients had succumbed, while 27 (84.4%) survived. The 5-year OS rate showed no statistically significant difference between the MSD and UD groups (84.8 ± 10.0 vs. 82.4 ± 9.2%, p = 0.674). In conclusion, the application of UC-MSCs in the treatment of R/R SAA in PBSC transplantation is reliable and safe, they had no graft rejection, low incidence of severe GVHD which may have been contributed by the co-infusion of MSC.

During hematopoietic stem cell transplantation (HSCT), ATG depletes T cells in-vivo to improve engraftment and prevent graft-versus-host disease (GVHD). Here, we compared the clinical efficacy of two different types of ATGs: thymoglobulin and anti-human T-lymphocyte immunoglobulin (Grafalon). A total of 469 patients who received haploidentical transplantation were enrolled in this retrospective study. We applied a propensity score (PS)-matched analysis and 209 patients were assigned to each group. Clinical outcomes were compared between two groups and primary outcome was overall survival (OS). There was no significant difference in OS between two groups. Within the first 180 days after HSCT, Grafalon was associated with lower incidences of Epstein-Barr virus (EBV) viremia (31.6 vs. 54.5%, P < 0.0001) and cytomegalovirus viremia (CMV) viremia (54.5 vs. 67.9%, P = 0.005) compared to thymoglobulin. Patients receiving Grafalon had a higher rate of moderate/severe chronic GVHD (26.3 vs. 18.2%, P = 0.046). However, the incidences of engraftment failure, grade II-IV acute GVHD, relapse, non-relapse mortality (NRM), and GVHD-free relapse-free survival (GRFS) did not differ greatly between groups. In the subgroup analysis, Grafalon improved the OS of lymphoid malignancies with young ages (< 40 years old) (HR, 0.55; P = 0.04) or with a high/very high disease risk index (HR, 0.36; P = 0.04). In the myeloid cohort, Grafalon reduced NRM in the patients who received non-female for male transplantation grafts (HR, 0.17; P = 0.02). Our results suggest the two types of ATG may differentially influence transplant outcomes and it may optimize ATG selection according to the condition of patients.

Objective: To establish an acute graft-versus-host disease (aGVHD) model in aged mice after non-myeloablative haploidentical peripheral blood stem cell transplantation (haplo-PSCT). Methods: C57BL/6 (H-2b) male mice aged 6-8 weeks were used as donor mice, and CB6F1 (H-2b×d) female mice aged 14-16 months were used as recipient mice. The donor mice were injected subcutaneously with rehuman granulocyte-colony stimulating factor (rhG-CSF) 5 days before transplantation for hematopoietic stem cell mobilization.The recipient mice were divided into control group (CG), spleen cell low-dose group (SL), spleen cell medium-dose group (SM) and spleen cell high-dose group (SH) according to random number table method, with 16 rats in each group, all of which received total linear accelerator X-ray irradiation (TBI) with a total dose of 6 Gy. Peripheral blood mononuclear cells (PBMC) and spleen cells of different doses (0.5×107/each, 1.0×107/each and 2.0×107/each in SL group, SM group and SH group, respectively) were transfused through the tail vein within 4 hours after TBI, and only the same amount of normal saline was transfused in CG group. After transplantation, the survival and weight changes of mice in each group were observed for 30 days, and the changes of blood routine were monitored regularly. Mice peripheral blood was collected 21 days after transplantation to detect the chimerism rate of the donor. Hematoxylin-eosin staining was performed on the skin, liver and colon of mice 21 days after transplantation to analyze the histopathological changes of aGVHD target organs. Results: All the mice in each group were successfully transplanted. After TBI, the weight and activity of mice in all groups decreased, and the phenomenon of bone marrow suppression appeared. During the observation period, all mice in CG group and SL group survived, 3 mice in SM group died with survival time of (26.0±5.8) days, and 6 mice in SH group died with survival time of (20.9±7.3) days. The body weight of mice in SH group was lower than that in CG group, SL group and SM group 21days after transplantation [(25.0±0.7), (25.5±0.4), (25.0±1.4) vs (20.8±0.8) g, all P<0.05]. Compared with CG group, SL group and SM group, the levels of leukocyte, erythrocyte, hemoglobin and platelet in SH group decreased 21 days after transplantation (all P<0.05). There was no significant difference in donor chimerism rate among SL group, SM group and SH group [(95.8%±0.8%), (95.5%±1.4%) and (95.1%±1.3%), respectively, all P>0.05]. Compared with CG group, SL group and SM group, the tissue structure of aGVHD target organs in SH group was severely damaged, with a large number of inflammatory cells infiltratedand higher histopathological scores than SL group and SM group (all P<0.05). Conclusion: For aging CB6F1 mice, after 6 Gy TBI pretreatment with linear accelerator X-ray, PBMC (1×107/each) and spleen cells (2.0×107/each) were injected to successfully induce aGVHD model after non-myelablative haplo-PSCT.
目的： 构建老龄小鼠非清髓性单倍体外周血造血干细胞移植（haplo-PSCT）后的急性移植物抗宿主病（aGVHD）模型。 方法： 选用6~8周龄C57BL/6（H-2b）雄性小鼠作为供鼠，14~16月龄CB6F1（H-2b×d）雌性老龄鼠作为受鼠。供鼠于移植前5 d皮下注射人粒细胞集落刺激因子（rhG-CSF）进行造血干细胞动员；将受鼠按随机数字表法分为对照组（CG）、脾细胞低剂量组（SL）、脾细胞中剂量组（SM）、脾细胞高剂量组（SH），每组各16只，均接受总剂量为6 Gy的直线加速器X射线全身照射（TBI），照射后4 h内经尾静脉输注外周血单个核细胞（PBMC）和不同剂量的脾细胞（SL组、SM组和SH组分别为0.5×107/只、1.0×107/只和2.0×107/只），CG组仅输注等量生理盐水。移植后观察各组受鼠的生存情况及体重变化，观察期为30 d，并定期监测小鼠血常规变化。移植后21 d取小鼠外周血检测供体嵌合率。移植后21 d取小鼠颈背部皮肤、肝脏、结肠组织行苏木精-伊红染色，分析aGVHD靶器官的组织病理学变化情况。 结果： 各组小鼠均移植成功。各组小鼠TBI后体重、活动度均下降，并出现骨髓抑制现象。观察期内CG组和SL组小鼠全部存活，SM组死亡3只，生存时间为（26.0±5.8）d，SH组小鼠死亡6只，生存时间为（20.9±7.3）d。SH组小鼠体重呈持续下降的趋势，移植后21 d体重低于CG组、SL组和SM组［分别为（25.0±0.7）、（25.5±0.4）、（25.0±1.4）比（20.8±0.8）g，均P<0.05］。移植后21 d，与CG组、SL组和SM组相比，SH组小鼠白细胞、红细胞、血红蛋白及血小板水平降低（均P<0.05）。SL组、SM组和SH组供体嵌合率差异无统计学意义［分别为（95.8%±0.8%）、（95.5%±1.4%）和（95.1%±1.3%），均P>0.05］。与CG组、SL组、SM组相比，SH组aGVHD靶器官组织结构破坏严重，大量炎性细胞浸润，且组织病理学评分高于SL组、SM组（均P<0.05）。 结论： 对于老龄CB6F1小鼠，给予直线加速器X线6 Gy TBI预处理之后，输注PBMC（1×107/只）、脾细胞（2.0×107/只）能成功诱导出非清髓性haplo-PSCT后aGVHD模型。.

The quality and quantity of hematopoietic stem cells in apheresis products are essential to the success of peripheral blood hematopoietic stem cell transplantation (PB-HSCT). While the flow cytometry measurement of CD34+ cells as a golden standard for stem cell count is labor and cost-intensive, hematopoietic progenitor cell number evaluated by XN Sysmex series automated hematology analyzers (XN-HPC) is suggested as a surrogate marker.
We evaluated the correlation and consistency of XN-HPC and CD34+ cell count in apheresis samples from both allogeneic donors and autologous patients during PB-HSCT.
Good correlation and consistency were observed between XN-HPC and CD34+ cell counts in harvests collected from healthy donors (R = .852) rather than autologous patients (R = .375). Subgroup analysis showed that the correlation was especially poor when autologous patients used plerixafor as an additional mobilizer or were diagnosed with multiple myeloma (MM). In the setting of allogeneic transplantation, the correlation coefficients were even better in samples from non-first-round apheresis (R = .951), with high white blood cell (WBC) counts (R = .941), or having successful engraftment within 2 weeks (R = .895). ROC analysis suggested that an optimal XN-HPC count of 1127 × 106 /L best predicted a sufficient yield of CD34+ stem cells, with diagnostic sensitivity and specificity being 92% and 72%, respectively (AUC = 0.852).
XN-HPC is a sufficient quantitative marker for stem cell assessment of harvest yield in allogeneic but not autologous HSCT.